Ana Paula Martins
Research Subjects
Ana Paula Martins has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carmona Araújo
Med.ULisboa ‐ Research Institute for Medicines, Faculty of Pharmacy University of Lisbon Lisbon Portugal
3 shared publications - José Pedro Guerreiro
Cientis, Lisbon, Portugal, Rua Marechal Saldanha, 1, Lisbon, 1649-069, Portugal
3 shared publications - João Goulão
ICAD ‐ Institute on Addictive Behaviours and Dependencies, P.I. Lisbon Portugal
3 shared publications - Maria Rute Horta
Centre for Medicines Information and Health Interventions (CEDIME), Infosaúde, Associação Nacional das Farmácias, 1249-069 Lisboa, Portugal
3 shared publications - Suzete Costa
Escola Nacional de Saúde Pública (ENSP), Universidade NOVA de Lisboa, Lisboa, Portugal
3 shared publications - Afonso Cavaco
Faculty of Pharmacy of the Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa, 1649-003, Portugal
2 shared publications
Latest Publications
- 19 July 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (11) , 3225-3235
Morbimortality consequences of use and misuse of psychoactive medicines in Portugal
Aims: To characterize the morbidity and mortality consequences of psychoactive medicines use and misuse in Portugal. Methods: Retrospective multisource database study to estimate the risk of psychoactive medicine‐related deaths, emergency department admissions, serious poisoning calls and serious adverse drug reaction reports, including combination with alcohol and illicit drugs. Results: Most intentional exposures to psychoactive medicines involving combinations ( n = 5973; 70.2%), antidepressants ( n = 5441; 67.1%) or any prescription opioid ( n = 355; 67.4%) resulted in serious poisonings (i.e., medical assistance advised). The risk of serious poisoning was higher for exposures involving substance combinations (relative risk [RR] = 1.12; confidence interval [95% CI): 1.10–1.14), antidepressants (RR = 1.04; 95% CI: 1.02–1.05) and alcohol and/or illicit drugs (RR = 1.18; 95% CI: 1.15–1.21). Among 6737 psychoactive medicine‐related deaths, 166 (2.5%) were identified where the medicine contributed to the fatal outcome. The risk of contribution to death was higher in cases involving substance combinations (RR = 9.03; 95% CI: 3.71–21.94), antidepressants (RR = 3.20; 95% CI: 2.28–4.49), and alcohol and/or illicit drugs (RR = 1.88; 95% CI: 1.36–2.61). Emergency department admission caused by misuse of a psychoactive medicine ( n = 5826) were more likely to involve benzodiazepines/z‐drugs (RR = 2.40; 95% CI: 2.30–2.51) or antidepressants (RR = 1.86; 95% CI: 1.80–1.93). Conclusions: Psychoactive medicine misuse in Portugal frequently occurs alongside polysubstance use and is associated with substantial health risks. Public health strategies should prioritize addressing high‐risk medicine combinations and therapeutic groups most often found to trigger negative outcomes. This may be achieved by targeted prevention efforts integrated into health system design.
- 19 July 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (11) , 3225-3235
Morbimortality consequences of use and misuse of psychoactive medicines in Portugal
Aims: To characterize the morbidity and mortality consequences of psychoactive medicines use and misuse in Portugal. Methods: Retrospective multisource database study to estimate the risk of psychoactive medicine‐related deaths, emergency department admissions, serious poisoning calls and serious adverse drug reaction reports, including combination with alcohol and illicit drugs. Results: Most intentional exposures to psychoactive medicines involving combinations ( n = 5973; 70.2%), antidepressants ( n = 5441; 67.1%) or any prescription opioid ( n = 355; 67.4%) resulted in serious poisonings (i.e., medical assistance advised). The risk of serious poisoning was higher for exposures involving substance combinations (relative risk [RR] = 1.12; confidence interval [95% CI): 1.10–1.14), antidepressants (RR = 1.04; 95% CI: 1.02–1.05) and alcohol and/or illicit drugs (RR = 1.18; 95% CI: 1.15–1.21). Among 6737 psychoactive medicine‐related deaths, 166 (2.5%) were identified where the medicine contributed to the fatal outcome. The risk of contribution to death was higher in cases involving substance combinations (RR = 9.03; 95% CI: 3.71–21.94), antidepressants (RR = 3.20; 95% CI: 2.28–4.49), and alcohol and/or illicit drugs (RR = 1.88; 95% CI: 1.36–2.61). Emergency department admission caused by misuse of a psychoactive medicine ( n = 5826) were more likely to involve benzodiazepines/z‐drugs (RR = 2.40; 95% CI: 2.30–2.51) or antidepressants (RR = 1.86; 95% CI: 1.80–1.93). Conclusions: Psychoactive medicine misuse in Portugal frequently occurs alongside polysubstance use and is associated with substantial health risks. Public health strategies should prioritize addressing high‐risk medicine combinations and therapeutic groups most often found to trigger negative outcomes. This may be achieved by targeted prevention efforts integrated into health system design.
- Open Access
- 29 July 2024
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2369319
Use and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal
Although psychoactive medicines (PMed) are needed in several psychiatric conditions, their use and misuse bear risks. We aimed at estimating the prevalence of PMed use and misuse. Data on all PMed prescribed in 2017 and dispensed in community pharmacies of the Lisbon and Tagus Valley region of Portugal (ARSLVT) were extracted from ARSLVT medicines’ dispensing database. For 21 PMed among prescription opioids, benzodiazepines and z-drugs (BZDR), antidepressants (AD) and anticonvulsants (AC), we estimated the number of users of each PMed, and assessed PMed misuse by a set of proxy indicators for studying this practice: chronic use (use of ≥180 DDD during the study period) of PMed intended for short-term treatments, concomitant use of several PMed, in particular if involving long-term (≥ 30 days) opioid analgesic (OA) use, and doctor shopping (patients consulting several physicians in order to have access to a quantity higher than intended by each prescriber). Data were analysed using descriptive statistics and hypothesis testing, and multivariate logistic regression was used to explore potential factors affecting long-term concomitant treatment of chronic OA with other PMed. PMed use prevalence was 21.7%: 6.6% for OA, 12.7% for benzodiazepines (BZD), 5.3% for AD and 2.8% for AC. BZDR were mainly prescribed in primary care and OA in hospital outpatients. Chronic use of PMed was observed in 25%, especially with sertraline and buprenorphine for opioid use disorder (long-term treatment), and lorazepam (short-term treatment). About 56.6% of OA chronic users were long-term concurrent users with other PMed, mainly BZDR. Risk of abuse was low for BZDR, whilst four opioids had meaningful doctor shopping indicators – fentanyl, opioid use disorder buprenorphine, morphine and hydromorphone. BZD are the main PMed used in ARSLVT, often chronically, especially lorazepam. Prevalence of OA use is low, although with higher risk of misuse than BZDR. Concomitant use of several PMed is frequent.
- 29 July 2024
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2369319
Open AccessUse and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal
Although psychoactive medicines (PMed) are needed in several psychiatric conditions, their use and misuse bear risks. We aimed at estimating the prevalence of PMed use and misuse. Data on all PMed prescribed in 2017 and dispensed in community pharmacies of the Lisbon and Tagus Valley region of Portugal (ARSLVT) were extracted from ARSLVT medicines’ dispensing database. For 21 PMed among prescription opioids, benzodiazepines and z-drugs (BZDR), antidepressants (AD) and anticonvulsants (AC), we estimated the number of users of each PMed, and assessed PMed misuse by a set of proxy indicators for studying this practice: chronic use (use of ≥180 DDD during the study period) of PMed intended for short-term treatments, concomitant use of several PMed, in particular if involving long-term (≥ 30 days) opioid analgesic (OA) use, and doctor shopping (patients consulting several physicians in order to have access to a quantity higher than intended by each prescriber). Data were analysed using descriptive statistics and hypothesis testing, and multivariate logistic regression was used to explore potential factors affecting long-term concomitant treatment of chronic OA with other PMed. PMed use prevalence was 21.7%: 6.6% for OA, 12.7% for benzodiazepines (BZD), 5.3% for AD and 2.8% for AC. BZDR were mainly prescribed in primary care and OA in hospital outpatients. Chronic use of PMed was observed in 25%, especially with sertraline and buprenorphine for opioid use disorder (long-term treatment), and lorazepam (short-term treatment). About 56.6% of OA chronic users were long-term concurrent users with other PMed, mainly BZDR. Risk of abuse was low for BZDR, whilst four opioids had meaningful doctor shopping indicators – fentanyl, opioid use disorder buprenorphine, morphine and hydromorphone. BZD are the main PMed used in ARSLVT, often chronically, especially lorazepam. Prevalence of OA use is low, although with higher risk of misuse than BZDR. Concomitant use of several PMed is frequent.
- Open Access
- 1 August 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (15) , 6496
Real-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management between Pharmacies and Primary Care in Portugal: A Multicenter Pragmatic Controlled Trial (USFarmácia®)
There is evidence of the efficacy of collaborative health interventions with pharmacies and primary care providers but little of its real-world effectiveness. We aimed to assess the effectiveness and discuss the design and challenges of hypertension and hyperlipidemia management between pharmacies and primary care providers using real-world data exchange between providers and experimental bundled payment. This was a pragmatic, quasi-experimental controlled trial. We collected patient-level data from primary care prescription claims and Electronic Medical Record databases, a pharmacy claims database, and patient telephone surveys at several time points. The primary outcomes were changes in blood pressure and total cholesterol. We used matched controls with difference-in-differences estimators in a Generalized Linear Model (GLM) and controlled interrupted time series (CITS). We collected additional data for economic and qualitative studies. A total of 6 Primary Care Units, 20 pharmacies, and 203 patients entered the study. We were not able to observe significant differences in the effect of intervention vs. control. We experienced challenges that required creative strategies. This real-world trial was not able to show effectiveness, likely due to limitations in the primary care technology which affected the sample size. It offers, however, valuable lessons on methods, strategies, and data sources, paving the way for more real-world effectiveness trials to advance value-based healthcare.
- 1 August 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (15) , 6496
Open AccessReal-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management between Pharmacies and Primary Care in Portugal: A Multicenter Pragmatic Controlled Trial (USFarmácia®)
There is evidence of the efficacy of collaborative health interventions with pharmacies and primary care providers but little of its real-world effectiveness. We aimed to assess the effectiveness and discuss the design and challenges of hypertension and hyperlipidemia management between pharmacies and primary care providers using real-world data exchange between providers and experimental bundled payment. This was a pragmatic, quasi-experimental controlled trial. We collected patient-level data from primary care prescription claims and Electronic Medical Record databases, a pharmacy claims database, and patient telephone surveys at several time points. The primary outcomes were changes in blood pressure and total cholesterol. We used matched controls with difference-in-differences estimators in a Generalized Linear Model (GLM) and controlled interrupted time series (CITS). We collected additional data for economic and qualitative studies. A total of 6 Primary Care Units, 20 pharmacies, and 203 patients entered the study. We were not able to observe significant differences in the effect of intervention vs. control. We experienced challenges that required creative strategies. This real-world trial was not able to show effectiveness, likely due to limitations in the primary care technology which affected the sample size. It offers, however, valuable lessons on methods, strategies, and data sources, paving the way for more real-world effectiveness trials to advance value-based healthcare.
- Open Access
Protocol for a scoping review on misuse of psychoactive medicines and its consequences
Introduction: Misuse of psychoactive medicines, especially prescription opioids, but also benzodiazepines, hypnotics and sedatives, has become a significant public health issue in some countries, especially in the USA, where it has been extensively documented, as well as in Canada and Australia. However, in the European Union (EU) published literature on the topic is scarce and heterogeneous regarding definitions, sources of data, tools and methods of analysis. The aim of this scoping review is to map the key concepts on psychoactive medicines’ misuse and examine the existing body of evidence on this topic in the EU. Data on the possible consequences of medicines’ misuse—adverse drug reactions, poisonings, hospitalisations and deaths—will also be analysed. Methods and analysis: The scoping review will follow the framework of Arksey and O’Malley, further developed by Levac et al and the Joanna Briggs Institute. The search strategy, developed by the authors, includes querying three electronic databases—PubMed, Web of Science and Scopus—using keywords and the Medical Subject Headings, for evidence published in English, French, Spanish or Portuguese between 2011 and 2020. Additionally, articles from PubMed alerts and other sources will also be considered. The results of the scoping review will describe the currently available evidence regarding misuse of medicines at EU level. Ethics and dissemination: Since the scoping review methodology focuses on published data, this study does not require ethical approval. We will publish our findings in a peer-reviewed journal and plan to disseminate our work in conferences and scientific meetings. Registration details: This scoping review protocol is registered in the Open Science Framework (OSF; see https://osf.io/fzr9u ) and has also been shared as a preprint in this free and open-source project management repository. It is available at https://doi.org/10.31219/osf.io/y3s4q .
Open AccessProtocol for a scoping review on misuse of psychoactive medicines and its consequences
Introduction: Misuse of psychoactive medicines, especially prescription opioids, but also benzodiazepines, hypnotics and sedatives, has become a significant public health issue in some countries, especially in the USA, where it has been extensively documented, as well as in Canada and Australia. However, in the European Union (EU) published literature on the topic is scarce and heterogeneous regarding definitions, sources of data, tools and methods of analysis. The aim of this scoping review is to map the key concepts on psychoactive medicines’ misuse and examine the existing body of evidence on this topic in the EU. Data on the possible consequences of medicines’ misuse—adverse drug reactions, poisonings, hospitalisations and deaths—will also be analysed. Methods and analysis: The scoping review will follow the framework of Arksey and O’Malley, further developed by Levac et al and the Joanna Briggs Institute. The search strategy, developed by the authors, includes querying three electronic databases—PubMed, Web of Science and Scopus—using keywords and the Medical Subject Headings, for evidence published in English, French, Spanish or Portuguese between 2011 and 2020. Additionally, articles from PubMed alerts and other sources will also be considered. The results of the scoping review will describe the currently available evidence regarding misuse of medicines at EU level. Ethics and dissemination: Since the scoping review methodology focuses on published data, this study does not require ethical approval. We will publish our findings in a peer-reviewed journal and plan to disseminate our work in conferences and scientific meetings. Registration details: This scoping review protocol is registered in the Open Science Framework (OSF; see https://osf.io/fzr9u ) and has also been shared as a preprint in this free and open-source project management repository. It is available at https://doi.org/10.31219/osf.io/y3s4q .
- Open Access
- 14 December 2021
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 18 (8) , 3338-3349
Pharmacy interventions on COVID-19 in Europe: Mapping current practices and a scoping review
- 14 December 2021
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 18 (8) , 3338-3349
Open AccessPharmacy interventions on COVID-19 in Europe: Mapping current practices and a scoping review
- Open Access
- 24 June 2021
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 43 (6) , 1660-1682
Defining clinical pharmacy and support activities indicators for hospital practice using a combined nominal and focus group technique
Background Although clinical pharmacy is a crucial part of hospital pharmacist’s day-to-day activity, its performance is not usually subject to a holistic assessment. Objective To define a set of relevant and measurable clinical pharmacy and support activities key performance indicators (cpKPI and saKPI, respectively). Setting Portuguese Hospital Pharmacies. Method After a comprehensive literature review focusing on the metrics already in use in other countries, several meetings with directors of hospital pharmacies were conducted to obtain their perspectives on hospital pharmacy practices and existing metrics. Finally, five rounds with a panel of 8 experts were performed to define the final set of KPIs, where experts were asked to score each indicator’ relevance and measurability, and encouraged to suggest new metrics. Main outcome measure The first Portuguese list of KPIs to assess pharmacists’ clinical and support activities performance and quality in hospital pharmacies. Results A total of 136 KPIs were assessed during this study, of which 57 were included in the original list and 79 were later added by the expert panel. By the end of the study, a total of 85 indicators were included in the final list, of which 40 are considered to be saKPI, 39 cpKPI and 6 neither. Conclusion A set of measurable KPIs was established to allow for benchmarking within and between Portuguese hospital Pharmacies and to elevate professional accountability and transparency. Future perspectives include the use of both cpKPIs and saKPIs on a national scale to identify the most efficient performances and areas of possible improvement.
- 24 June 2021
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 43 (6) , 1660-1682
Open AccessDefining clinical pharmacy and support activities indicators for hospital practice using a combined nominal and focus group technique
Background Although clinical pharmacy is a crucial part of hospital pharmacist’s day-to-day activity, its performance is not usually subject to a holistic assessment. Objective To define a set of relevant and measurable clinical pharmacy and support activities key performance indicators (cpKPI and saKPI, respectively). Setting Portuguese Hospital Pharmacies. Method After a comprehensive literature review focusing on the metrics already in use in other countries, several meetings with directors of hospital pharmacies were conducted to obtain their perspectives on hospital pharmacy practices and existing metrics. Finally, five rounds with a panel of 8 experts were performed to define the final set of KPIs, where experts were asked to score each indicator’ relevance and measurability, and encouraged to suggest new metrics. Main outcome measure The first Portuguese list of KPIs to assess pharmacists’ clinical and support activities performance and quality in hospital pharmacies. Results A total of 136 KPIs were assessed during this study, of which 57 were included in the original list and 79 were later added by the expert panel. By the end of the study, a total of 85 indicators were included in the final list, of which 40 are considered to be saKPI, 39 cpKPI and 6 neither. Conclusion A set of measurable KPIs was established to allow for benchmarking within and between Portuguese hospital Pharmacies and to elevate professional accountability and transparency. Future perspectives include the use of both cpKPIs and saKPIs on a national scale to identify the most efficient performances and areas of possible improvement.
- 1 June 2019
- Published by Elsevier in Primary Care Diabetes
- Vol. 13 (3) , 221-232
Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study
- 1 June 2019
- Published by Elsevier in Primary Care Diabetes
- Vol. 13 (3) , 221-232
Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study
- Open Access
- 21 March 2019
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 12 (1) , 1-12
Diabetes policies and pharmacy-based diabetes interventions in Portugal: a comprehensive review
Pharmacy-based interventions are complex public health endeavors which include, but are not restricted to, the conventional medication supply role. In diabetes, such interventions may improve patients’ outcomes. The aim of this study was to review relevant policies and research developed in Portugal directed at pharmacy-based diabetes interventions, and to inform future policies, practice and research in collaborative practice with primary care. An exploratory review of diabetes legislation and policy papers, as well as a comprehensive review in Embase, MEDLINE (via Ovid and PubMed), Google Scholar, and grey literature until November 2017 was performed. Sixteen policy papers and 10 studies were included in the analysis. Positive evidence from pharmacy interventions was retrieved concerning screening individuals at risk, screening uncontrolled patients, managing diabetes, and supporting self-monitoring. Some consistency in favorable findings, but also room for improvements in health policies, intervention design and research methods, were observed.
- 21 March 2019
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 12 (1) , 1-12
Open AccessDiabetes policies and pharmacy-based diabetes interventions in Portugal: a comprehensive review
Pharmacy-based interventions are complex public health endeavors which include, but are not restricted to, the conventional medication supply role. In diabetes, such interventions may improve patients’ outcomes. The aim of this study was to review relevant policies and research developed in Portugal directed at pharmacy-based diabetes interventions, and to inform future policies, practice and research in collaborative practice with primary care. An exploratory review of diabetes legislation and policy papers, as well as a comprehensive review in Embase, MEDLINE (via Ovid and PubMed), Google Scholar, and grey literature until November 2017 was performed. Sixteen policy papers and 10 studies were included in the analysis. Positive evidence from pharmacy interventions was retrieved concerning screening individuals at risk, screening uncontrolled patients, managing diabetes, and supporting self-monitoring. Some consistency in favorable findings, but also room for improvements in health policies, intervention design and research methods, were observed.
- Open Access
- 1 March 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (3) , 823-828
Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications
- 1 March 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (3) , 823-828
Open AccessHurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications